¼¼°èÀÇ ¾È°Ë¿° ½ÃÀå º¸°í¼­(2025³â)
Blepharitis Global Market Report 2025
»óǰÄÚµå : 1764264
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,253,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,039,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,824,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¾È°Ë¿° ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ °­·ÂÇÑ ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù. 2029³â¿¡´Â CAGR 12.2%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 15¾ï 4,000¸¸ ´Þ·¯·Î ¼ºÀåÀÌ ¿¹ÃøµË´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ¼ºÀåÀº °³º°È­ Ä¡·áÁ¢±Ù¹ýÀÇ Áøº¸, Æí¸®ÇÑ ÀçÅÃÄ¡·á ¿É¼Ç¿¡ ´ëÇÑ ±âÈ£ °íÁ¶, ȯÀÚÀǽÄÀÇ Çâ»ó, ½ÅÈï½ÃÀåÀ¸·ÎÀÇ È®´ë, ±ÔÁ¦½ÂÀÎÀÇ ÇÕ¸®È­ µî¿¡ ±âÀÎÇÑ´Ù°í »ý°¢µË´Ï´Ù. ÀÌ ±â°£¿¡ ¿¹»óµÇ´Â ÁÖ¿ä µ¿Çâ¿¡´Â °­·Â ÆÞ½º±¤ Ä¡·á, AI¸¦ Ȱ¿ëÇÑ È­»ó Áø´Ü, ÀÚµ¿ ¾È°Ë ÃÔ¿µ ½Ã½ºÅÛ, ¸ÖƼ¸ð´Þ Ä¡·á Àü·«, »ý¹°Á¦Á¦ °³¹ß µî Çõ½ÅÀû Ä¡·á ÃâÇöÀÌ Æ÷ÇԵ˴ϴÙ.

¾ÆÀÌÄɾ ´ëÇÑ ÀǽÄÀÇ °íÁ¶´Â ÇâÈÄ ¼ö³â°£ ¾È°Ë¿° ½ÃÀåÀÇ È®´ë¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾ÆÀÌ Äɾ´Â, ´«ÀÇ °Ç°­°ú ½Ã·ÂÀÇ À¯Áö ¹× Çâ»óÀ» ¸ñÀûÀ¸·Î ÇÑ ´Ù¾çÇÑ ¼­ºñ½º, Ä¡·á, ½ÇõÀÌ Æ÷ÇԵ˴ϴÙ. ¾çÈ£ÇÑ ½Ã·ÂÀº °³ÀÎÀÇ ÀÚ¸³, ±³À°ÀÇ ´Þ¼º, ÀÏÀÇ »ý»ê¼º, »îÀÇ Áú Àüü¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϱ⠶§¹®¿¡ ÀǽÄÀÇ Çâ»óÀÌ ÇʼöÀûÀÔ´Ï´Ù. ½Ã·Â ¹®Á¦¸¦ ¹æÄ¡Çϸé ÀÏ»ó»ýȰÀ̳ª Çо÷¼ºÀû, ÀÏÀÇ È¿À²¿¡ ¾Ç¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù. ¾È°Ë¿° Ä¡·á´Â Áõ»óÀÇ Á¶±â ¹ß°ßÀ» ÃËÁøÇϰí, ÀϰüµÈ ´«²¨Ç® À§»ýÀ» Àå·ÁÇϸç, Àû±â Ä¡·á¸¦ ÅëÇØ ¾È±¸°ÇÁ¶Áõ, °á¸·¿° µî ÇÕº´ÁõÀ» ¿¹¹æÇÔÀ¸·Î½á Á¾ÇÕÀûÀÎ ¾ÆÀÌÄɾ ±â¿©ÇÕ´Ï´Ù. ¿¹¸¦ µé¸é, 2024³â 10¿ù, ¿µ±¹À» °ÅÁ¡À¸·Î ÇÏ´Â ´ÜüÀÎ AOP(Association of Optometrists : °Ë¾È»ç Çùȸ)´Â, ¿µ±¹¿¡¼­ ½Ã·Â »ó½ÇÀÚÀÇ ¼ö´Â 2035³â±îÁö ¾à 280¸¸ ¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖÀ¸¸ç, À̰ÍÀº 2022³â°ú ºñ±³ÇØ 27% Áõ°¡ÇÑ´Ù°í º¸°íÇß½À´Ï´Ù. ÀÌ ¶§¹®¿¡ ¾ÆÀÌÄɾ ´ëÇÑ ÀǽÄÀÇ °íÁ¶°¡ ¾È°Ë¿° ½ÃÀåÀÇ ¼ºÀå¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¾È°Ë¿° ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº °æÀïÀ» °­È­Çϱâ À§ÇØ Ç¥Àû Ç×±â»ýÃæ¾àÀ̳ª Çõ½ÅÀûÀÎ ¾È°ú¿ë Á¦Á¦ µîÀÇ ½Å±Ô Ä¡·áÀÇ °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. Çõ½ÅÀûÀÎ ¾È°ú¿ë Á¦Á¦¿¡´Â ´« ÁúȯÀÇ Ä¡·á È¿°ú, ¾ÈÀü¼º, ȯÀÚÀÇ ÄèÀû¼ºÀ» ³ôÀ̱â À§ÇØ ¼³°èµÈ ¼±ÁøÀûÀÎ ¾à¹° Àü´Þ ½Ã½ºÅÛ°ú Á¶¼º¹°ÀÌ Æ÷ÇԵ˴ϴÙ. ¿¹¸¦ µé¸é, 2023³â 7¿ù, ¹Ì±¹ÀÇ ¹ÙÀÌ¿À ÀǾàǰ ȸ»çÀÎ Tarsus Pharmaceuticals Inc.´Â, µ¥¸ðµ¦½º ¾È°Ë¿°ÀÇ Ä¡·á·Î¼­ XDEMVY(·ÎƼ¶ó³Ú Á¡¾È¾×) 0.25%ÀÇ FDA ½ÂÀÎÀ» ÃëµæÇß½À´Ï´Ù. ÀÌÀü¿¡´Â TP-03À¸·Î ¾Ë·ÁÁ® ÀÖ´ø XDEMVY´Â µ¥¸ðµ¦½º ¾È°Ë¿°ÀÇ ±Ùº» ¿øÀÎÀÎ µ¥¸ðµ¦½º Áøµå±â¸¦ Á÷Á¢ Ç¥ÀûÀ¸·Î ÇÏ´Â FDA°¡ ½ÂÀÎÇÑ ÃÖÃÊÀÌÀÚ À¯ÀÏÇÑ Ä¡·áÀÔ´Ï´Ù. À̹ø ½ÂÀÎÀº 833¸íÀÇ È¯ÀÚ°¡ Âü¿©ÇÑ 2°³ÀÇ Áß¿äÇÑ ÀÓ»ó°Ë»ç(Saturn-1°ú Saturn-2)¿¡¼­ ¾òÀº È®½ÇÇÑ ÀÓ»ó µ¥ÀÌÅÍ¿¡ ÀÇÇØ µÞ¹ÞħµÇ°í ÀÖÀ¸¸ç, À§¾à°ú ºñ±³ÇÏ¿© ÇöÀúÇÑ Áõ»óÀÇ °³¼±°ú ³ôÀº ¸ñ´ú¹ÌÀÇ ¿ÏÄ¡À²ÀÌ ½ÇÁõµÇ¾ú½À´Ï´Ù. ±ÇÀå ¿ë·®Àº 1ȸ 1¹æ¿ïÀ» 1ÀÏ 2ȸ, 6ÁÖ µ¿¾È Á¡¾ÈÇÏ´Â °ÍÀÔ´Ï´Ù. XDEMVYÀÇ Àο뼺Àº ÀϹÝÀûÀ¸·Î ¾çÈ£Çϸç, °æµµÀÇ ½Ã¸° µíÇÑ ÅëÁõ°ú È­²ö°Å¸²ÀÌ °¡Àå ¸¹ÀÌ º¸°íµÇ°í ÀÖ´Â ºÎÀÛ¿ëÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ ¹× Àü·«

Á¦4Àå ½ÃÀå : ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ªÀüÀï ¹× °ü¼¼, Äڷγª ¹× ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼® ¹× Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº° ¹× ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ ¹× ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å· ¹× ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹® ¹× Àü·«

Á¦36Àå ºÎ·Ï

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Blepharitis is a common eye disorder characterized by inflammation of the eyelids, typically at the base of the eyelashes. It often leads to symptoms such as redness, itching, crusting, and a gritty or burning feeling in the eyes. This condition is usually chronic and may be caused by bacterial infections, skin disorders like dandruff, or blocked oil glands.

The primary types of blepharitis include anterior blepharitis, posterior blepharitis, and mixed blepharitis. Anterior blepharitis affects the front edge of the eyelid, where the eyelashes grow. Treatment options commonly include eye cleansers, artificial tears, and antibiotic therapy. Diagnosis methods such as physical examinations and comprehensive eye evaluations are employed across various healthcare settings, including hospitals and specialty clinics.

The blepharitis market research report is one of a series of new reports from The Business Research Company that provides blepharitis market statistics, including blepharitis industry global market size, regional shares, competitors with a blepharitis market share, blepharitis market segments, market trends and opportunities, and any further data you may need to thrive in the blepharitis industry. This blepharitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The blepharitis market size has grown strongly in recent years. It will grow from $0.86 billion in 2024 to $0.97 billion in 2025 at a compound annual growth rate (CAGR) of 12.5%. The growth during the historic period can be attributed to the rise in eye-related disorders, an aging global population, heightened awareness of ocular hygiene, increased screen time, and a surge in allergic and dermatological conditions.

The blepharitis market size is expected to see strong growth in the next few years. It will grow to $1.54 billion in 2029 at a compound annual growth rate (CAGR) of 12.2%. The growth in the forecast period can be attributed to the advancement of personalized treatment approaches, a growing preference for convenient at-home care options, increased patient awareness, expansion into emerging markets, and streamlined regulatory approvals. Key trends expected during this period include the emergence of innovative treatments such as intense pulsed light therapy, AI-powered diagnostic imaging, automated eyelid imaging systems, multi-modal treatment strategies, and the development of biologic drugs.

The growing awareness of eye care is expected to drive the expansion of the blepharitis market in the coming years. Eye care encompasses a variety of services, treatments, and practices designed to preserve and enhance eye health and vision. Increased awareness is essential, as good vision plays a critical role in an individual's independence, educational achievement, work productivity, and overall quality of life. Unaddressed vision problems can negatively impact daily functioning, academic performance, and job efficiency. Managing blepharitis contributes to comprehensive eye care by promoting early detection of symptoms, encouraging consistent eyelid hygiene, and preventing complications such as dry eye and styes through timely treatment. For example, in October 2024, the Association of Optometrists (AOP), a UK-based organization, reported that the number of individuals living with sight loss in the UK is projected to rise to approximately 2.8 million by 2035-a 27% increase compared to 2022. Therefore, increasing awareness around eye care is significantly contributing to the growth of the blepharitis market.

Leading companies in the blepharitis market are emphasizing the development of novel therapies, including targeted anti-parasitic agents and innovative ophthalmic formulations, to strengthen their competitive position. Innovative ophthalmic formulations involve advanced drug delivery systems and compositions designed to enhance treatment efficacy, safety, and patient comfort in managing eye disorders. For example, in July 2023, Tarsus Pharmaceuticals Inc., a US-based biopharmaceutical company, received FDA approval for XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis. Previously known as TP-03, XDEMVY is the first and only FDA-approved therapy that directly targets Demodex mites-the underlying cause of Demodex blepharitis. The approval was supported by robust clinical data from two pivotal trials (Saturn-1 and Saturn-2) involving 833 patients, demonstrating notable symptom improvement and a higher rate of complete collarette cure compared to placebo. The recommended dosage is one drop in each eye twice daily for six weeks. XDEMVY is generally well tolerated, with mild stinging or burning being the most commonly reported side effects.

In July 2023, LianBio, a US-based biotechnology company, entered into a partnership with Tarsus Pharmaceuticals to broaden access to XDEMVY for the treatment of Demodex blepharitis and meibomian gland disease in regions with substantial unmet medical needs. The collaboration aims to leverage strong clinical evidence and address the large patient population requiring effective treatment options. Tarsus Pharmaceuticals Inc. is a US-based pharmaceutical company dedicated to developing innovative therapies, with a strong focus on eye care.

Major players in the blepharitis market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Viatris Inc., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Thea Pharmaceuticals Ltd, Harrow Inc., URSAPHARM Arzneimittel GmbH, Tarsus Pharmaceuticals Inc., Scope Ophthalmic Ltd, Santen Pharmaceutical Co Ltd., NovaBay Pharmaceuticals Inc., InSite Vision Incorporated, MiBo Medical Group, and Nicox SA.

North America was the largest region in the blepharitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in blepharitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the blepharitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The blepharitis market consists of revenues earned by entities by providing services such as antibiotic therapy, topical corticosteroids, topical and oral antibiotics, ointments, and eye cleansers. The market value includes the value of related goods sold by the service provider or included within the service offering. The blepharitis market also includes sales of steroid eye drops, ointments, eyelid cleansers, lid scrubs, and warm compress masks. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Blepharitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on blepharitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for blepharitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The blepharitis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Blepharitis Market Characteristics

3. Blepharitis Market Trends And Strategies

4. Blepharitis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Blepharitis Growth Analysis And Strategic Analysis Framework

6. Blepharitis Market Segmentation

7. Blepharitis Market Regional And Country Analysis

8. Asia-Pacific Blepharitis Market

9. China Blepharitis Market

10. India Blepharitis Market

11. Japan Blepharitis Market

12. Australia Blepharitis Market

13. Indonesia Blepharitis Market

14. South Korea Blepharitis Market

15. Western Europe Blepharitis Market

16. UK Blepharitis Market

17. Germany Blepharitis Market

18. France Blepharitis Market

19. Italy Blepharitis Market

20. Spain Blepharitis Market

21. Eastern Europe Blepharitis Market

22. Russia Blepharitis Market

23. North America Blepharitis Market

24. USA Blepharitis Market

25. Canada Blepharitis Market

26. South America Blepharitis Market

27. Brazil Blepharitis Market

28. Middle East Blepharitis Market

29. Africa Blepharitis Market

30. Blepharitis Market Competitive Landscape And Company Profiles

31. Blepharitis Market Other Major And Innovative Companies

32. Global Blepharitis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Blepharitis Market

34. Recent Developments In The Blepharitis Market

35. Blepharitis Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â